Issue 36, 2025, Issue in Progress

Inhibitory potential of pentagalloyl glucose against efflux pumps in Staphylococcus aureus

Abstract

Antibiotic resistance in Gram-positive priority pathogens is mediated by a diverse set of mechanisms such as target protection, antibiotic inactivation, decreased uptake, antibiotic efflux, etc. In Staphylococcus aureus, efflux pumps of the major facilitator superfamily (MFS) expel various antibiotics and multiple efflux pumps are activated upon antibiotic exposure. Efflux pump inhibitors (EPIs) that can act as antibiotic adjuvants are proposed to be promising solutions to tackle antibiotic resistance. In this study, in silico screening of 17 967 phytochemical compounds from Indian medicinal plants (IMPPAT 2.0) against four key MFS efflux pumps activated by fluoroquinolone exposure (NorA, NorB, NorC, and SdrM) followed by in vitro validation identified a tannin derivative, pentagalloyl glucose (PGG), as a potential efflux pump inhibitor (EPI) with high binding affinity. Molecular docking scores (≤−16.383 kcal mol−1) and MM/GBSA binding affinities (≤−100.62 kcal mol−1) indicate a strong interaction between PGG and its targeted efflux pumps. PGG forms stable interactions via hydrogen bonding with key residues of NorA, including GLU222 and ASP307, which are crucial for proton-coupled transport. Likewise, it interacts with essential residues in NorB (SER147, ASN280), NorC (ASN276, LYS398), and SdrM (SER143, GLN283), forming strong hydrogen bonds that contribute to its inhibitory potential. The stability of PGG-bound complexes was confirmed through molecular dynamics simulations over 100 ns in triplicates, along with free energy landscape (FEL) and principal component analysis (PCA). Furthermore, PGG's synergistic action with ciprofloxacin, and effects on S. aureus growth dynamics were validated using the checkerboard assay, and time-kill kinetic studies, respectively. Following further structural optimization and in vivo studies, PGG can be considered a promising therapeutic candidate against multidrug-resistant S. aureus strains.

Graphical abstract: Inhibitory potential of pentagalloyl glucose against efflux pumps in Staphylococcus aureus

Supplementary files

Transparent peer review

To support increased transparency, we offer authors the option to publish the peer review history alongside their article.

View this article’s peer review history

Article information

Article type
Paper
Submitted
04 Jun 2025
Accepted
09 Aug 2025
First published
20 Aug 2025
This article is Open Access
Creative Commons BY-NC license

RSC Adv., 2025,15, 29377-29388

Inhibitory potential of pentagalloyl glucose against efflux pumps in Staphylococcus aureus

K. Harikumar, U. Singh, S. K. Ramaraj, L. A. Rekha, A. Nayak, P. Ghosh, R. Prasad, A. Philip, S. Sahu and S. Nelson-Sathi, RSC Adv., 2025, 15, 29377 DOI: 10.1039/D5RA03958D

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. You can use material from this article in other publications, without requesting further permission from the RSC, provided that the correct acknowledgement is given and it is not used for commercial purposes.

To request permission to reproduce material from this article in a commercial publication, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party commercial publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements